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OBJECTIVES: Primary percutaneous coronary intervention (PPCI) has become the 
preferred treatment option for acute ST-segment elevation myocardial infarction 
(STEMI). In 2009, over 18,000 PPCI procedures were performed in France. New 
antithrombotic therapies can potentially improve clinical outcomes and decrease costs. 
The HORIZONS-AMI study of bivalirudin demonstrated reduced clinical event rates 
(mortality and bleeding) compared to a heparin and GPI (HEP + GPI) regimen. The 
potential economic value of implementing bivalirudin in the PPCI setting is evaluated 
here from a French hospital perspective. METHODS: A budget impact model was 
developed to compare treatment of STEMI patients undergoing PPCI with either 
bivalirudin or HEP + GPI. Clinical data for the model were derived from the HORI-
ZONS trial database, and included 30-day event rates for major complications (non-
access site bleeding as deﬁned by trial protocol, Q-wave myocardial infarction, repeat 
PCI and coronary artery bypass graft procedures) and patient death. Non-access site 
bleeding was examined in light of decreased incidence of access site-related bleeding 
events associated with radial access PCI, a common practice in France. French cost 
and clinical practice data were derived from published sources. RESULTS: Overall 
average procedure and hospitalization cost per bivalirudin-treated patient (incorporat-
ing 7.2% provisional GPI use as per HORIZONS) was 38171, compared with 39201 
per HEP + GPI-treated patient. In extrapolating these beneﬁts to a typical French 
hospital of 200 PPCI patients per year, 2 deaths (1%), 3 minor non-access site bleeding 
events (1.4%), and 4 major non-access site bleeding events (1.9%) in patients would 
be averted if treated with bivalirudin. The total hospital budget impact of treating 200 
PPCI patients using a HEP + GPI based strategy is 1,840,2673. Introducing a bivali-
rudin-based strategy could save 3206,148 (11%) per year. CONCLUSIONS: Using a 
bivalirudin-based strategy in STEMI patients undergoing PPCI is associated with 
favorable clinical and economic outcomes when compared with HEP + GPI in a French 
hospital setting.
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OBJECTIVES: Evaluate the economic impact of the use of Levosimendan compared 
to Dobutamine, in patients with Acute Heart Failure (AHF) in Mexico. METHODS: 
Literature review was conducted to compare the resource utilization for AHF patients. 
Further, a budget impact analysis was done to demonstrate economic advantages of 
using Levosimendan, compared to Dobutamine. An economic model was built based 
on days in general ward (GW) and intensive care unit (ICU) as parameters. The 
number of days in GW and/or ICU was multiplied by the cost per GW and ICU, taken 
from the Mexican Federal Authority data. RESULTS: Length of stay was shorter in 
case of Levosimendan treated patients compared to Dobutamine ones (2.88 vs. 3.22 
in ICU, and 4.15 vs. 5.74 in GW), according to the ALARM-HF study (abstract 
presented at the ESC-Hear Failure annual congress 2007, Germany). The medical costs 
per patient were US$7418 if treated with Levosimendan and US$8680 for a patient 
receiving Dobutamine, thus a US$1262 difference. In Mexico, the cost of the treatment 
of AHF patients is US$500 (1 vial) for Levosimendan and US$76 (10 vials) for Dobu-
tamine (US$424 difference). The ﬁnal result, including the cost of the drug, shows a 
difference of 838 USD per patient in favour of the treatment with Levosimendan. 
According to international and national literature, the eligible AHF population to 
receive inotropic treatment in Mexico is approximately 90,240. Assuming that the 
whole population were treated with Dobutamine, the total cost, would be US$790.1 
million. If treated with Levosimendan, the total would be US$714.8 million. This 
represents potential savings of US$75.6 USD million for the Mexican Public Health 
System. CONCLUSIONS: The use of Levosimendan, in comparison with Dobuta-
mine, has demonstrated to represent a very important source of potential savings for 
the Mexican public health system in patients with AHF.
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OBJECTIVES: To determine the cost-effectiveness of Heart Failure (HF) clinics com-
pared to standard care for HF patients in Ontario, Canada. METHODS: We per-
formed a cost-effectiveness analysis, with a 12-year time horizon, from the perspective 
of the Ontario Ministry of Health. We compared a standard care cohort, consisting 
of all patients admitted to hospital with HF in 2005, to a hypothetical cohort treated 
in HF clinics. Survival curves describing the natural history of HF were constructed 
using mortality estimates from EFFECT study. Survival beneﬁts and resource uptake 
associated with HF clinics were estimated from a meta-analysis of published trials. 
HF clinics costs were obtained by costing of a representative clinic in Ontario. Health-
related costs associated with physician visits, hospitalizations, emergency department 
visits, same day surgeries and medication use, were determined through linkage to 
administrative databases. Outcome measures included life expectancy, costs (in 2008 
CAD$) and the incremental cost-effectiveness ratio (ICER). A budget impact analyses 
was performed to estimate affordability. RESULTS: The systematic review determined 
that HF clinics were associated with a 29% reduction in all-cause mortality (risk ratio 
[RR] 0.71; 95% Conﬁdence Interval [CI] 0.56–0.91) but a 12% increase in hospital-
izations (RR 1.12; 95% CI 0.92–1.135). The cost of care in HF clinics was $52 per 
30 patient-days. Projected life-expectancy of HF clinic patients was 3.91 years, com-
pared to 3.21 years for standard care. The 12 year cumulative cost per patient in the 
HF clinic group was $66,532 versus $53,638 in the standard care group. The ICER 
was $18,259/life year gained. The average annual cost for HF clinic implementation 
was $17 million in Ontario. CONCLUSIONS: Multi-disciplinary HF clinics reduce 
mortality and increase life expectancy. Despite increasing overall costs due to increased 
late hospitalizations, HF clinics appear to be a cost effective way of delivering ambula-
tory care to HF patients.
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COMPARATIVE EFFECTIVENESS OF LOW-MOLECULAR-WEIGHT-
HEPARINS: META-ANALYSIS AND PHARMACOECONOMIC ASSAY
Kildonaviciute G1, Kadusevicius E1, Varanaviciene B2
1Kaunas Medical University, Kaunas, Lithuania, 2Kaunas Medical University Hospital, Kaunas, 
Lithuania
OBJECTIVES: To compare efﬁcacy, safety and consumption of low-molecular-weight 
heparins (LMWHs) in Lithuania and to develop pharmacoeconomic decision model 
based on meta-analysis data. METHODS: Review and meta-analysis of published 
randomized control trials which directly compared the safety and efﬁcacy of low 
molecular weight heparins (LMWH) i.e. Nadroparin, Enoxaparin, Dalteparin, was 
conducted by two independent reviewers using inclusion/exclusion criteria based on 
the objectives of research. Statistical software MedCalc was used to perform the 
estimations of the following values. We calculated the value of ﬁxed effects and 
random effects odds ratio (95% conﬁdence interval (CI)) for each trial for the com-
posite end point. Afterwards, pharmacoeconomic decision modelling was imple-
mented, which was based on meta-analysis data. Cost-minimization assay was 
accomplished using reference pricing methodology. RESULTS: Enoxaparin vs. Dalte-
parin: 4 studies, involving 471 patients, were eligible (ﬁxed effects odds ratio 1.447 
[95% CI 0.957–2.281]). Nadroparin vs. Enoxaparin: 3 studies, involving 1118 
patients, were involved (ﬁxed effects odds ratio 1.360 [95% CI 1.050–1.762]). Dalte-
parin vs. Nadroparin: 2 studies, involving 294 patients, were eligible (ﬁxed effects 
odds ratio 0.577 [95% CI 0.337–0.988]). None of low-molecular-weight heparins 
demonstrated signiﬁcant superiority when compared with each other, so group of 
LMWHs was suitable for pharmacoeconomic analysis and reference pricing imple-
mentation. Dalteparin single DDD price was set as reference price, as it was the least 
expensive option. Introducing the reference pricing for low-molecular-weight heparins 
would result in total savings of 1,830–2,070 thousand LTL in Lithuania yearly. The 
implementation of reference pricing would enable to decrease the total expenditures 
on LMWHs by 29.28%–31.98%. CONCLUSIONS: In the accomplished meta-anal-
ysis, none of low-molecular-weight heparins demonstrated signiﬁcant superiority 
when compared with each other. Meta-analysis results could be applied to support 
pharmacoeconomic decision-modelling and that would allow decreasing health-care 
expenditures in the whole country.
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OBJECTIVES: To estimate total costs of stay in a skilled nursing facility (SNF) to 
Medicare, beneﬁciaries, and private payors 1 year after a venous thromboembolism 
(VTE) event in patients with total hip/knee replacement (THR/TKR), and to compare 
costs of stays in short- versus long-term facilities. METHODS: Based on 2004–2006 
national Medicare claims, all fee-for-service Medicare patients older than age 65 years 
who underwent THR/TKR were identiﬁed. The 1-year follow-up cost of care for 
patients with a VTE event (including deep vein thrombosis [DVT] and/or pulmonary 
embolism [PE]) during initial hospitalization was calculated for stays in short- versus 
long-term facilities or SNFs. Individual costs were identiﬁed as Medicare cost, total 
cost to beneﬁciaries, and total cost to private payors. Costs were compared between 
patients with and without a VTE event. Risk adjustment was done using regression 
techniques, controlling for baseline characteristics between patients with and without 
VTE events. RESULTS: In patients who underwent THR/TKR (n = 155,197), 1.8% 
had postoperative VTE during initial hospitalization. Almost 70% (n = 1950) of these 
patients had DVT, 24% (n = 642) PE, and 6% (n = 153) both DVT and PE. Almost 
20% of patients with DVT, 6.3% with PE, and 8.5% with both DVT and PE were 
discharged to an SNF. The 1-year total cost of an SNF stay for patients with VTE 
